Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis
Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
Electronic versions
DOI
There are concerns with the National Institute for Health and Care Excellence (NICE) conditional approval process with respect to the quality and reliability of the methods of evidence generation, analysis, and reporting; and on the increasing focus on OwR (only with research) in preference to OiR (only in research). Our study critically appraises the methods, quality, and risk of bias of the evidence generated in response to NICE conditionally approved technologies.
| Original language | English |
|---|---|
| Title of host publication | OP41 Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis. |
| Subtitle of host publication | Abstracts from the HTAi 2024 Meeting in Seville, Spain |
| Publisher | International Journal of Technology Assessment in Health Care. |
| Volume | 40 |
| Edition | Special Issue S1 |
| DOIs | |
| Publication status | Published - 7 Jan 2025 |
| Event | Health Technology Assessment International (HTAi) 2024 Meeting: Oral presentation - Seville, Spain Duration: 15 Jun 2024 → 19 Jun 2024 https://htai.org/event/htai-2024-annual-meeting/ |
Conference
| Conference | Health Technology Assessment International (HTAi) 2024 Meeting |
|---|---|
| Country/Territory | Spain |
| City | Seville |
| Period | 15/06/24 → 19/06/24 |
| Internet address |